Danshen injection prevents heart failure by attenuating post-infarct remodeling

Wang, Lingyan; Yu, Jiahui; Fordjour, Patrick Asare; Gao, Hui; Li, Yanyan; Li, Lingyan; Zhu, Yan; Gao, Xiumei; Fan, Guanwei

doi:10.1016/j.jep.2017.04.027

Cited by 30 publications

(23 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimental work and clinical trials both showed that danshen have potent cardioprotective effects against HF. 11,[20][21][22] However, the protective mechanisms of danshen need to be fully elucidated. Based on transcriptome technique, we explored the regulatory effects of danshen on AMI-induced HF by in vivo and in vitro experiments.…”

Section: Discussionmentioning

confidence: 99%

“…33,34 Danshen, the dried root or rhizome of Salvia miltiorrhiza Bge, is an ancient antipyretic traditional Chinese medicine and mostly used to ameliorate blood circulation and dispel blood stasis. 21 gene Tlr4, Irf5, Cd86, Tlr9, Tlr2, Spp1, Cd80 and Tlr8. Of the eight genes, Tlr4, Tlr9 and Tlr8 are involved in the progression of HF 7,35,36 ; silencing of the transcription factor Irf5 may be used to ameliorate HF 37 ; immune response-related genes CD80 and CD86 promise to be effective new immunotherapeutic targets in inflammation related to heart 38 ; MI could induce strong transcriptional activation of Spp1.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Danshen (Salvia miltiorrhiza) restricts MD2/TLR4‐MyD88 complex formation and signalling in acute myocardial infarction‐induced heart failure

Wang

Guo

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Heart failure (HF) represents a major public health burden. Inflammation has been shown to be a critical factor in the progression of HF, regardless of the aetiology. Disappointingly, the majority of clinical trials targeting aspects of inflammation in patients with HF have been largely negative. Many clinical researches demonstrate that danshen has a good efficacy on HF, and however, whether danshen exerts anti‐inflammatory effects against HF remains unclear. In our study, the employment of a water extracted and alcohol precipitated of danshen extract attenuated cardiac dysfunction and inflammation response in acute myocardial infarction‐induced HF rats. Transcriptome technique and validation results revealed that TLR4 signalling pathway was involved in the anti‐inflammation effects of danshen. In vitro, danshen reduced the release of inflammatory mediators in LPS‐stimulated RAW264.7 macrophage cells. Besides, the LPS‐stimulated macrophage conditioned media was applied to induce cardiac H9C2 cells injury, which could be attenuated by danshen. Furtherly, knock‐down and overexpression of TLR4 were utilized to confirm that danshen ameliorated inflammatory injury via MyD88‐dependent TLR4‐TRAF6‐NF‐κB signalling pathway in cardiomyocytes. Furthermore, by utilizing co‐immunoprecipitation, danshen was proved to suppress MD2/TLR4 complex formation and MyD88 recruitment. In conclusion, our results demonstrated that danshen ameliorates inflammatory injury by controlling MD2/TLR4‐MyD88 complex formation and TLR4‐TRAF6‐NF‐κB signalling pathway in acute myocardial infarction‐induced HF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Danshen (Salvia miltiorrhiza) restricts MD2/TLR4‐MyD88 complex formation and signalling in acute myocardial infarction‐induced heart failure

Wang

Guo

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…e studies of TCM for the treatment of HF have been carried out for quite a long while and most of them, including animal experiments, clinical trials, or pharmacological studies, have indicated the efficacy of TCM at the basis of CHFST [30][31][32]. Fuzi are widely used as a TCM herb in the formulae of TCM based on the essence of heart-yang deficiency of heart failure, such as various decoctions made according to the principles of TCM syndrome, injections, and Chinese patent medicines [18,19,24,25,[33][34][35][36][37].…”

Section: Summary Of Evidencementioning

confidence: 99%

Efficacy and Safety of Fuzi Formulae on the Treatment of Heart Failure as Complementary Therapy: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials

Yang

Song

Gao

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Heart failure is a major public health problem worldwide nowadays. However, the morbidity, mortality, and awareness of heart failure are not satisfied as well as the status of current treatments. According to the standard treatment for chronic heart failure (CHFST), Fuzi (the seminal root of Aconitum carmichaelii Debx.) formulae are widely used as a complementary treatment for heart failure in clinical practice for a long time. We are aiming to assess the efficacy and safety of Fuzi formulae (FZF) on the treatment of heart failure according to high-quality randomized controlled trials (RCTs). Methods. RCTs in PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang Database were searched from their inception until June 2019. In addition, the U.S. National Library of Medicine (clinicaltrials.gov) and the Chinese Clinical Trial Registry (http://www.chictr.org.cn) were also searched. We included RCTs that test the efficacy and safety of FZF for the treatment of heart failure, compared with placebo, CHFST, or placebo plus CHFST. The methodological quality of included studies were evaluated by the Cochrane Collaboration’s tool for assessing risk of bias. RCTs with Cochrane risk of bias (RoB) score ≥4 were included in the analysis. The meta-analysis was conducted through RevMan 5.2 software. The GRADE approach was used to assess the quality of the evidence. Results. Twelve RCTs with 1490 participants were identified. The studies investigated the efficacy and safety of FZF, such as FZF plus the CHFST vs placebo plus CHFST (n = 4), FZF plus CHFST vs CHFST (n = 6), FZF plus digoxin tablets (DT) plus CHFST vs placebo plus DT plus CHFST (n = 1), and FZF plus placebo plus CHFST vs placebo plus DT plus CHFST (n = 1). Meta-analysis indicated that FZF have additional benefits based on the CHFST in reducing plasma NT-proBNP level, MLHFQ scores, Lee’s heart failure scores (LHFs), and composite cardiac events (CCEs). Meanwhile, it also improved the efficacy on TCM symptoms (TCMs), NYHA functional classification (NYHAfc), 6MWD, and LVEF. Adverse events were reported in 6 out of 12 studies without significant statistical difference. However, after assessing the strength of evidence, it was found that only the quality of evidence for CCEs was high, and the others were either moderate or low or very low. So we could not draw confirmative conclusions on its additional benefits except CCEs. Further clinical trials should be well designed to avoid the issues that were identified in this study. Conclusion. The efficacy and additional benefits of FZF for CCEs were certain according to the high-quality evidence assessed through GRADE. However, the efficacy and additional benefits for the other outcomes were uncertain judging from current studies. In addition, the safety assessment has a great room for improvement. Thus, further research studies are needed to find more convincing proofs.

show abstract

“…17 Danshen, the dried root of rhizome of Salvia miltiorrhiza Burge, is a traditional Chinese medicine used mainly for treating cardiovascular diseases, including HCM. [18][19][20][21][22] Tanshinone IIA, the most bioactive lipidsoluble compound of Danshen, has been found to exert a wide variety of cardiovascular benefits, including antioxidative, anti-inflammatory, anti-coagulation, anti-apoptosis, endothelial/myocardial protective, vasodilating, and anti-atherosclerosis effects. 23 Previous studies using cultured cardiomyocytes have shown that tanshinone IIA can significantly prevent cardiac hypertrophy induced by isoproterenol.…”

Section: Introductionmentioning

confidence: 99%

Danshen (Salvia miltiorhiza) inhibits Leu27 IGF‐II‐induced hypertrophy in H9c2 cells

Velmurugan

et al. 2020

Environmental Toxicology

View full text Add to dashboard Cite

In this study, we used ICI 182 780 (ICI), an estrogen receptor (ER) antagonist, to investigate the estrogenic activity of Danshen, and to further explored whether Danshen extract can block Leu27IGF‐II‐induced hypertrophy in H9c2 cardiomyoblast cells. We first used an IGF‐II analog Leu27IGF‐II, which specifically activates IGF2R signaling cascades and induces H9c2 cardiomyoblast cell hypertrophy. However, Danshen extract completely inhibited Leu27IGF‐II‐induced cell size increase, ANP and BNP hypertrophic marker expression, and IGF2R induction. We also observed that Danshen extract inhibited calcineurin protein expression and NFAT3 nuclear translocation, leading to suppression of Leu27IGF‐II‐induced cardiac hypertrophy. Moreover, the anti‐Leu27IGF‐II‐IGF2R signaling effect of Danshen was totally reversed by ICI, which suggest the cardio protective effect of Danshen is mediated through estrogen receptors. Our study suggests that, Danshen exerts estrogenic activity, and thus, it could be used as a selective ER modulator in IGFIIR induced hypertrophy model.

show abstract

Danshen injection prevents heart failure by attenuating post-infarct remodeling

Cited by 30 publications

References 50 publications

Danshen (Salvia miltiorrhiza) restricts MD2/TLR4‐MyD88 complex formation and signalling in acute myocardial infarction‐induced heart failure

Danshen (Salvia miltiorrhiza) restricts MD2/TLR4‐MyD88 complex formation and signalling in acute myocardial infarction‐induced heart failure

Efficacy and Safety of Fuzi Formulae on the Treatment of Heart Failure as Complementary Therapy: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials

Danshen (Salvia miltiorhiza) inhibits Leu27 IGF‐II‐induced hypertrophy in H9c2 cells

Contact Info

Product

Resources

About